Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Recent Advances in Anti-Cancer Drugs
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Recent Advances in Anti-Cancer Drugs

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 3157

Special Issue Editor

Dr. Christiana Neophytou

E-Mail Website
Guest Editor
Apoptosis and Cancer Chemoresistance Laboratory, Basic and Translational Cancer Research Center, Department of Life Sciences, European University Cyprus, Nicosia 2404, Cyprus
Interests: targeted cancer therapy; apoptosis; metastasis; cancer chemoresistance; pancreatic cancer; breast cancer; lung cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is a pleasure for me to invite you to contribute to this Special Issue in IJMS that aims to collect the latest information on a wide variety of novel anti-cancer therapies. Despite all the advances of the last decades, many challenges remain to target aggressive and resistant cancer. The design of new drugs or improvement of current therapies, remains at the forefront of cancer research. In addition, identifying the underlying causes of cancer chemoresistance as well as the discovery of biomarkers that predict patient response to treatment, are pivotal for enhancing therapeutic efficacy.

This Special issue aims at reporting the latest developments on anti-cancer therapy, with special emphasis on targeting difficult to treat cancers, including but not limited to triple negative breast cancer, lung, pancreatic cancer and glioblastoma. Efforts to evaluate the efficacy of anti-cancer drugs and reverse chemoresistance in the pre-clinical setting will also be included. Potential contributors are invited to submit papers on the following topics:

  • Synergistic anti-cancer therapy, especially involving small molecule inhibitors and agents derived from natural sources
  • Therapeutic approaches to reverse cancer chemoresistance as well as identification of underlying mechanisms of resistance
  • Recent developments in immunotherapy
  • Predictive biomarkers, especially derived from liquid biopsies, to determine therapeutic efficacy
  • Anti-cancer drugs targeting metastatic dormancy
  • Agents that modulate the tumor microenvironment for improving therapeutic efficacy
  • Modern approaches in preclinical drug discovery including 3D culture systems

Experimental studies in in vitro and in vivo models and review articles, are all welcome for consideration.

Dr. Christiana M. Neophytou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • combination therapy in cancer
  • small molecule inhibitors in cancer
  • anti-cancer agents derived from natural sources
  • immunotherapy advances in cancer therapy
  • targeting metastatic dormancy
  • modulation of the tumor microenvironment
  • 3D model approaches in cancer research
  • predictive biomarkers for cancer chemoresistance

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

21 pages, 4795 KiB  
Article
Silver Complexes of Miconazole and Metronidazole: Potential Candidates for Melanoma Treatment
by Małgorzata Fabijańska, Agnieszka J. Rybarczyk-Pirek, Justyna Dominikowska, Karolina Stryjska, Dominik Żyro, Magdalena Markowicz-Piasecka, Małgorzata Iwona Szynkowska-Jóźwik, Justyn Ochocki and Joanna Sikora
Int. J. Mol. Sci. 2024, 25(10), 5081; https://doi.org/10.3390/ijms25105081 - 7 May 2024
Viewed by 274
Abstract
Melanoma, arguably the deadliest form of skin cancer, is responsible for the majority of skin-cancer-related fatalities. Innovative strategies concentrate on new therapies that avoid the undesirable effects of pharmacological or medical treatment. This article discusses the chemical structures of [(MTZ)2AgNO3 [...] Read more.
Melanoma, arguably the deadliest form of skin cancer, is responsible for the majority of skin-cancer-related fatalities. Innovative strategies concentrate on new therapies that avoid the undesirable effects of pharmacological or medical treatment. This article discusses the chemical structures of [(MTZ)2AgNO3], [(MTZ)2Ag]2SO4, [Ag(MCZ)2NO3], [Ag(MCZ)2BF4], [Ag(MCZ)2SbF6] and [Ag(MCZ)2ClO4] (MTZ—metronidazole; MCZ—miconazole) silver(I) compounds and the possible relationship between the molecules and their cytostatic activity against melanoma cells. Molecular Hirshfeld surface analysis and computational methods were used to examine the possible association between the structure and anticancer activity of the silver(I) complexes and compare the cytotoxicity of the silver(I) complexes of metronidazole and miconazole with that of silver(I) nitrate, cisplatin, metronidazole and miconazole complexes against A375 and BJ cells. Additionally, these preliminary biological studies found the greatest IC50 values against the A375 line were demonstrated by [Ag(MCZ)2NO3] and [(MTZ)2AgNO3]. The compound [(MTZ)2AgNO3] was three-fold more toxic to the A375 cells than the reference (cisplatin) and 15 times more cytotoxic against the A375 cells than the normal BJ cells. Complexes of metronidazole with Ag(I) are considered biocompatible at a concentration below 50 µmol/L. Full article
(This article belongs to the Special Issue Recent Advances in Anti-Cancer Drugs)
►▼ Show Figures

Figure 1

Review

Jump to: Research

20 pages, 1523 KiB  
Review
Prognostic Value of Monocarboxylate Transporter 1 Overexpression in Cancer: A Systematic Review
by Ana Silva, Mónica Costa Cerqueira, Beatriz Rosa, Catarina Sobral, Filipa Pinto-Ribeiro, Marta Freitas Costa, Fátima Baltazar and Julieta Afonso
Int. J. Mol. Sci. 2023, 24(6), 5141; https://doi.org/10.3390/ijms24065141 - 7 Mar 2023
Cited by 6 | Viewed by 2166
Abstract
Energy production by cancer is driven by accelerated glycolysis, independently of oxygen levels, which results in increased lactate production. Lactate is shuttled to and from cancer cells via monocarboxylate transporters (MCTs). MCT1 works both as an importer and an extruder of lactate, being [...] Read more.
Energy production by cancer is driven by accelerated glycolysis, independently of oxygen levels, which results in increased lactate production. Lactate is shuttled to and from cancer cells via monocarboxylate transporters (MCTs). MCT1 works both as an importer and an extruder of lactate, being widely studied in recent years and generally associated with a cancer aggressiveness phenotype. The aim of this systematic review was to assess the prognostic value of MCT1 immunoexpression in different malignancies. Study collection was performed by searching nine different databases (PubMed, EMBASE, ScienceDirect, Scopus, Cochrane Library, Web of Science, OVID, TRIP and PsycINFO), using the keywords “cancer”, “Monocarboxylate transporter 1”, “SLC16A1” and “prognosis”. Results showed that MCT1 is an indicator of poor prognosis and decreased survival for cancer patients in sixteen types of malignancies; associations between the transporter’s overexpression and larger tumour sizes, higher disease stage/grade and metastasis occurrence were also frequently observed. Yet, MCT1 overexpression correlated with better outcomes in colorectal cancer, pancreatic ductal adenocarcinoma and non-small cell lung cancer patients. These results support the applicability of MCT1 as a biomarker of prognosis, although larger cohorts would be necessary to validate the overall role of MCT1 as an outcome predictor. Full article
(This article belongs to the Special Issue Recent Advances in Anti-Cancer Drugs)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop